Trial · NCT03654768
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Molecular Response 4.5 (MR4.5) | Single Agent TKI | 3 | percentage of participants | ||
| Rate of Molecular Response 4.5 (MR4.5) | TKI + Ruxolitinib | 14 | percentage of participants | ||
| Overall Survival | Single Agent TKI | 100 | 95% Confidence Interval NA to NA | percentage of participants | |
| Overall Survival | TKI + Ruxolitinib | 97 | 95% Confidence Interval 80 to 100 | percentage of participants | |
| Progression-free Survival | Single Agent TKI | 89 | 95% Confidence Interval 74 to 96 | percentage of participants | |
| Progression-free Survival | TKI + Ruxolitinib | 89 | 95% Confidence Interval 73 to 96 | percentage of participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Single Agent TKI | Constipation | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | TKI + Ruxolitinib | Constipation | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Single Agent TKI | Fatigue | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | TKI + Ruxolitinib | Fatigue | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Single Agent TKI | Headache | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | TKI + Ruxolitinib | Headache | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Single Agent TKI | Hypertension | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | TKI + Ruxolitinib | Hypertension | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Single Agent TKI | Nausea | 0 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | TKI + Ruxolitinib | Nausea | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Single Agent TKI | Neutrophil count decreased | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | TKI + Ruxolitinib | Neutrophil count decreased | 2 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Single Agent TKI | Pancreatitis | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | TKI + Ruxolitinib | Pancreatitis | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03654768/results